STShinichiro Tsunoda

Shinichiro Tsunoda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shinichiro Tsunoda has a total of 85 co-authors. Here are the top co-authors by number of shared publications:

  • Masayasu Kitano

    Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine , Hyogo , Japan

    5 shared publications
  • Takahiro Yoshikawa

    Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine , Hyogo , Japan

    5 shared publications
  • Aki Nishioka

    Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine

    4 shared publications
  • Kiyoshi Matsui

    Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo Medical University, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan

    4 shared publications
  • Masahiro Sekiguchi

    Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine

    4 shared publications
  • Naoto Azuma

    Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine

    4 shared publications

Latest Publications

  • Immunology and targeted therapy in Castleman disease

    by Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki

    Castleman disease (CD) is a benign lymphoproliferative disease causing severe systemic inflammation. Interleukin-6 (IL-6) is a major pathogenesis of multicentric CD (MCD), but only 30-60% of patients respond to IL-6 inhibitors. Novel agents for IL-6 inhibitor-refractory cases are needed. Clinical data and samples are being collected on a large scale and the clinical, pathological and pathogenetic aspects are being elucidated. The pathological and clinical classification of CD is outlined. Focusing on idiopathic MCD (iMCD), this review identifies therapeutic targets and summarizes currently recommended drugs and promising therapeutic candidates. The pathogenesis of MCD has been implicated in the activation of the Janus kinase (JAK)-transcriptional signaling activator (STAT)3 pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt/mechanical target of rapamycin (mTOR) signaling pathway. iMCD-TAFRO (thrombocytopenia, anasarca, fever/elevated CRP, reticulin myelofibrosis/renal dysfunction, organ enlargement) is resistant to IL-6 inhibitors, and cyclosporine and mTOR inhibitors are sometimes effective. JAK inhibitors and mTOR inhibitors may be therapeutic agents for iMCD. Recently, we have shown that peripheral helper T (Tph) cell abnormalities are at the core of iMCD pathogenesis. Therapies targeting chemokine (C-X-C motif) ligand 13 (CXCL13) produced by Tph cells and blocking the Tph-CXCL13-B cell pathway may satisfy unmet need in refractory cases.


  • Open Access

    Association of HLA-DRB1 genotype with younger age onset and elder age onset rheumatoid arthritis in Japanese populations

    by Shomi Oka, Hiroshi Furukawa, Kota Shimada, Atsushi Hashimoto, Akiko Komiya, Shinichiro Tsunoda, Koichiro Saisho, Naoyuki Tsuchiya, Masao Katayama, Satoshi Shinohara, et al.

    Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by joint destructions and human leukocyte antigen (HLA)-DRB1 is an important genetic risk factor for RA and influences the phenotype of RA. The clinical features of elder age onset RA (EORA) were known to be different from those of younger age onset RA (YORA). Previous studies reported the different association pattern of DRB1 alleles with YORA or EORA. The associations of DRB1 genotype with these RA subsets remained almost unknown. We investigated the genotype association of DRB1 with YORA or EORA in Japanese populations. HLA genotyping was performed in Japanese RA patients and the association of allele or genotype carrier frequencies were analyzed. The genotype frequency of DRB1 ∗ 04:05/DRB1 ∗ 04:06 (P = .0204, OR 7.69, 95%CI 1.39–42.72), DRB1 ∗ 04:05/DRB1 ∗ 12:01 (P = .0050, OR 5.53, 95%CI 1.71–17.88), and DRB1 ∗ 04:05/DRB1 ∗ 15:01 (P = .0124, OR 3.34, 95%CI 1.39–8.02) in YORA was higher than EORA. However, the frequencies of DRB1 ∗ 01:01/DRB1 ∗ 04:05 in YORA was tended to be lower than EORA (P = .0784, OR 0.14, 95%CI 0.01–2.42). The gene dosage effect of the shared epitope alleles was detected in EORA, but not in YORA. Trans-complementing DQ heterodimer molecules, formed by DQA1 and DQB1 of the haplotypes with and without shared epitope alleles, might explain the higher genotype frequencies of “shared epitope /not shared epitope”. Linear regression analyses showed the primary role of DQB1 ∗ 04:01 allele for the age at onset of RA. This is the first report for the associations of DRB1 genotype with YORA or EORA in the Japanese population and the differential distribution of the genotypes was noted between these RA subsets. The involvement of DQ molecules for the age at onset of RA was suggested.


  • Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis

    by Aki Nishioka, Shinichiro Tsunoda, Takeo Abe, Takahiro Yoshikawa, Miki Takata, Masayasu Kitano, Kiyoshi Matsui, Ran Nakashima, Yuji Hosono, Koichiro Ohmura, et al.

    Objective: This study identified biomarkers that can be used to assess disease activity and response to therapy in patients with interstitial lung disease complicating anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive clinically amyopathic dermatomyositis (CADM). Methods: In 15 patients with interstitial lung disease complicating anti-MDA5 Ab-positive CADM, anti-MDA5 Ab, neopterin, interleukin (IL)-18, ferritin, and soluble interleukin 2 receptor (sIL-2R) levels were measured in cryopreserved serum specimens before and at multiple times after remission induction therapy, and their correlations were assessed. Results: Anti-MDA5 Ab, neopterin, IL-18, ferritin, and sIL-2R levels did not differ significantly between patients who survived and those who succumbed to the disease. In many cases, serum anti-MDA5 Ab titers were over the upper limit (over 150 index value) before treatment in the usual measuring method, and gradually decreased to the normal range at stable phase. Meanwhile, serum neopterin levels (21.6 [15.3-48.3] nmol/L) were significantly elevated in newly diagnosed patients and fell to 6.8 (5-11.4) nmol/L at 6 months after treatment introduction. Conclusions: Elevated serum neopterin as well as ferritin, sIL-2R, KL-6, and anti-MDA5 Ab titer might help identify patients with interstitial lung disease complicated with DM and might be useful in monitoring response to therapy.


  • A case of anti-PL-7 antibody positive polymyositis with thrombotic microangiopathy

    by Masao Tamura, Masayasu Kitano, Kouta Azuma, Kazuyuki Tsuboi, Takeo Abe, Chie Ogita, Yuichi Yokoyama, Tetsuya Furukawa, Takahiro Yoshikawa, Atsushi Saito, et al.

    症例は65歳女性.X-17年に間質性肺炎合併多発性筋炎と診断されステロイド薬が開始.X-8年に関節リウマチを合併しタクロリムス(Tac)が併用となっていた.X年2月上旬から全身倦怠感と高血圧が出現,さらに血液検査で,血小板減少,溶血性貧血,破砕赤血球,LDH高値,高クレアチニン血症を認めたことから,血栓性微小血管障害症(TMA)と診断.TMAの原因としてcalcineurin inhibitor(CNI)腎症を疑い,Tacを中止し血漿交換を開始した.以降,破砕赤血球は消失し,血小板減少,溶血性貧血は改善したが,高血圧,腎機能低下が遷延したため腎生検を施行.その結果はTMAの病理組織像であった.ただしCNI腎症としてはTacの血中濃度は既存の報告と比較し低く,また薬剤中止後も腎機能低下が遷延していた点が非定型的であった.後に抗PL-7抗体が陽性であることが判明.本症例は強皮症の診断基準は満たさなかったが,同抗体陽性例では強皮症を合併したとする報告がある.すなわち潜在的な強皮症素因を背景にCNI腎症が重篤化した可能性が示唆された.抗PL-7抗体陽性の患者にTacを投与する際はTMAの発症に十分留意する必要がある.


  • A case of anti-aminoacyl tRNA synthetase antibody syndrome complicated by hemophagocytic syndrome

    by Kota Azuma, Masao Tamura, Masafumi Kurajoh, Yuji Hosono, Ran Nakajima, Kazuyuki Tsuboi, Takeo Abe, Chie Ogita, Yuichi Yokoyama, Tetsuya Furukawa, et al.

    48歳,女性,主訴は発熱,全身倦怠感.2013年12月から38℃の発熱が出現し近医受診.間質性肺炎を指摘されるも経過観察となっていた.2014年1月に手指の皮疹,末梢血流障害が出現.成人Still病疑いと診断され,ベタメタゾン(0.5mg/day)とシクロスポリン(75mg/day)でコントロールされていた.2014年11月に全身倦怠感,発熱,頭痛などの症状出現.頭部MRIで下垂体腫大認め,採血でも抗下垂体抗体陽性のため自己免疫性下垂体炎と診断.当院での治療を希望されたため2015年5月当院内分泌科入院となったが,活動性は乏しく,無治療経過観察となった.発熱・間質性肺炎・レイノー症状・両側大腿内側部の筋痛などの症状あることから膠原病が疑われ,精査加療目的に当科転科となった.成人Still病は診断基準を満たすものではなく,現在の病態を正確に把握するため,ベタメタゾンとシクロスポリンは中止とした.入院時血液検査は抗ARS抗体陽性,筋原性酵素上昇を認めた.間質性肺炎を伴う抗ARS症候群と診断し,mPSL 500mg×3日間投与し,後療法はプレドニゾロン(PSL)35mg/dayで開始とした.その後症状は治まっていたが,3日後に再度発熱・筋痛が出現し汎血球減少も伴った.骨髄穿刺で貪食像を認めたため,血球貪食症候群(HPS)と考え,増悪に起因すると考え125mg/dayで再開.その後は発熱・筋痛は消失し再燃を認めていない.また汎血球減少に関しても治療後は3系統とも血球の改善を認めた.


  • A case of familial Mediterranean fever who complained of periodic fever and abdominal pain diagnosed by MEFV gene analysis

    by Chie Ogita, Kiyoshi Matsui, Dai Kisida, Mariko Kakudou, Masahide Yazaki, Akinori Nakamura, Kouta Azuma, Kazuyuki Tsuboi, Takeo Abe, Yuichi Yokoyama, et al.

    家族性地中海熱(Familial Mediterranean fever = FMF)は,持続時間が1~3日と比較的短い周期性発熱と無菌性の漿膜炎を主徴とする単一遺伝性自己炎症性疾患に含まれる.自己炎症性疾患は自己免疫疾患,感染症と異なり,自己抗体,自己反応性T細胞,および病原体は同定されず,病因としては獲得免疫ではなく,自然免疫系の異常と考えられている.FMFはMEFV(Mediterranean fever)遺伝子の異常に伴うインフラマソームの機能異常により,IL-1βの産生が起こる自己炎症が病態の中心にある.地中海沿岸地域で最も有病率が高いのだが,本邦でも多数の症例が報告されている.本邦では,1976年に初めて症例報告されたが,MEFV遺伝子変異を有する症例が記載されたのは2002年のShinozakiらおよびTomiyamaらが最初であり以後遺伝子解析を含めた症例の集積が進んでいる.明らかな性差はなく,常染色体劣性遺伝を呈することが多いとされている.臨床症状や発熱の周期性により,典型例と非典型例に区分されており,典型例の発症年齢は成人発症例が比較的多い.今回,家族歴がなく,周期的な発熱と腹痛を主訴とし,MEFV遺伝子解析からFMFと診断した1例を報告する.症例は本邦に多い成人発症であり,遺伝子解析後にコルヒチンにより治療し,良好な経過をとっている.

  • A case of HELLP syndrome at 34w-pregnancy with systemic lupus erythymatosus and antiphospholipid antibody syndrome; Importance of measurement of VW factor

    by Momo Maruoka, Shinichiro Tsunoda, Tetsuya Furukawa, Okuto Honda, Takahiro Yoshikawa, Kazuyuki Fujita, Yuki Sekiguchi, Chieri Satou, Atsushi Saitou, Aki Nishioka, et al.

    A 39-year-old woman was diagnosed with Systemic lupus erthymatosus (SLE) in 1993, and initially received 30 mg of prednisolone (PSL) daily as treatment. In 2012, the patient was diagnosed with pregnancy-induced hypertension (PIH) complecated with proteinurea, hypertension and pretibial edema at 24 weeks of gestation. At onset, protein urea was 1.6 g/day and she was given bed rest in the hospital with a protein-restricted and low salt diet, which led to a decrease in protein urea to approximately 1 g/day. At 34 weeks of gestation epigastric pain developed, and laboratory examinations showed liver dysfunction and low platelets. We made a diagnosis of hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome and performed an emergency cesarean procedure. Thereafter blood pressure was elevated, protein urea was 3.2 g/daily, anti-ds-DNA antibody level was elevated and serum C3/C4/CH50 was reduced, thus we gave. plasma exchange therapy, along with immunoadsorption and steroid pulse therapy (methyl-prednisolone 500 mg/daily for 3 days), as well as PSL at 30 mg/day. Overtime clinical symptoms and laboratory data gradually improved.


  • SAT0119 Effect of Abatacept on Bone Homeostasis and Osteopontin in Rheumatoid Arthritis

    by M. Kitano, S. Kitano, M. Ishizu, T. Furukawa, T. Yoshikawa, K. Fujita, Y. Katashima, C. Sato, A. Saito, A. Nishioka, et al.

    Background Abatacept (CTLA4-Ig) is a new therapeutic agent used for rheumatoid arthritis (RA). Recently, it is reported that CTLA-4 directly inhibits osteoclast formation. On the other hand, Osteopontin (OPN) is produced by activated T lymphocytes and has been recognized as one of the key molecules for osteoclastic bone-resorption in RA. However, the effect of abatacept on bone homeostasis and OPN production in RA is poorly understood. In this study, we investigated the effects of abatacept on biochemical markers of bone, serum soluble receptor activator of NF-kappa B ligand (sRANKL), osteoprotegerin (OPG), and plasma osteopontin (OPN) in patients with RA. Objectives To demonstrate the effect of abatacept on bone homeostasis in RA. Methods 24 patients with RA (19 females, 5 males; age 59.8±14.7 years; disease duration 6.1±8.0 years; stage 2.0±1.2; class 1.8±0.6; DAS28-CRP 4.6±1.4; SDAI 26.7±12.8; use of MTX 83%; average dose of MTX 5.9±3.3mg/week; use of PSL 71%; average dose of PSL 3.9±3.2mg/day) were started on treatment with abatacept for 24 weeks. All patients were biologics naïve. In addition, circulating levels of type I collagen cross-linked N-telopeptides (NTx), osteocalcin, sRANKL, OPG, and plasma OPNwere examined by ELISA at baseline and after 12 and 24 weeks. Results After 24 weeks of abatacepttreatment, DAS28-CRP and SDAI decreased significantly from the baseline (4.6±1.4 vs 2.5±0.9; pConclusions These findings suggest that abatacept improves systemic bone metabolism in patient with RA through the increase of bone formation markers and the decrease of bone degradation markers. We consider that these mechanism result from the regulation of OPN and RANKL expression in activated T lymphocytes. Consequently, abatacept may control osteoclastic-bone destruction in RA via the suppression of RANKL induced-osteoclastogenesis and OPN induced-osteoclast attachment of bone surface. Disclosure of Interest None Declared


  • Open Access

    Low-Density Lipoprotein Apheresis Therapy for Steroid- and Cyclosporine-Resistant Idiopathic Membranous Nephropathy

    by Yoshinori Sato, Shinichiro Tsunoda, Tsuyoshi Nozue, Qinya Pan, Harue Wakasugi, Ashio Yoshimura

    We herein report three cases of Nephrotic Syndrome (NS) with idiopathic membranous nephropathy (IMN) in which the patients were resistant to steroid (PSL) and cyclosporine (CyA) therapy. All three patients had a high risk of renal failure because of persistently high levels of proteinuria. We performed low-density lipoprotein apheresis (LDL-A) and achieved complete remission in two cases. The third patients developed NS relapse and a deteriorating renal function; however, withdrawal from dialysis therapy was achieved. There are no proven therapies for treating patients with PSL- and CyA-resistant IMN with acute deteriorating renal function or difficulties in maintaining fluid balance. We evaluated the treatment course and physiological mechanisms and reviewed similar cases in the pertinent literature.


  • A case of IgG4-positive multiorgan lymphoproliferative syndrome: dramatic perturbations of the CD8-positive T-cell repertoire in peripheral blood

    by S Tsunoda, A Yachie, H Wakasugi, K Matsushita, Y Yamaguchi, M Kawano

    (2010). A case of IgG4-positive multiorgan lymphoproliferative syndrome: dramatic perturbations of the CD8-positive T-cell repertoire in peripheral blood. Scandinavian Journal of Rheumatology: Vol. 39, No. 6, pp. 520-523.